PROJECT SUMMARY/ABSTRACT
Epstein-Barr virus (EBV) was discovered over 50 years ago because of research into the etiology of endemic
Burkitt lymphoma (BL). BL remains one of the most common and still frequently fatal pediatric cancers in sub-
Saharan Africa. A second critical co-factor in the etiology of BL is repeated infection with Plasmodium
falciparum (Pf) malaria. The exact cellular and molecular events that link these two pathogens to increase the
risk for BL and drive the c-myc translocation characteristic of BL remain to be elucidated. Without this
information, our understanding of the etiology of BL, a cancer called the Rosetta Stone for deciphering viral
oncogenesis, remains incomplete. The overall goal of our research is to understand why children living in
malaria endemic regions are at high risk for BL. Based on our studies in Kenya where we found children living
in a malaria endemic region were infected with EBV early in life, had higher EBV viral loads over time and that
malaria exposure has an independent effect on increasing EBV viral loads in children. Combined, these data
point to an important role for malaria infection in dysregulating EBV latency. To account for the effects of
malaria on EBV-infected B cells, we are proposing a variation of the GC model, termed the “Dysequilibrium
model of EBV persistence.” In our model, the excess of heme released during malaria infection binds to the B
cell transcription factor, Bach2 suppressing its activity. Release of Bach2 mediated suppression allows Blimp1
to orchestrate plasma cell differentiation. EBV would reactivate in terminally differentiated plasma cells
resulting in viremia and an elevated population of secondarily infected B cells. An increased frequency of EBV-
infected B cells in and of itself is not necessarily problematic but we have also observed high levels of the
enzyme—activation induced deaminase (AID)—in peripheral blood mononuclear cells (PBMC) in children living
in a malaria endemic region and dysregulation of AID expression in B cell subsets during acute malaria. The
critical molecular event that defines BL is the translocation of the c-myc oncogene into the immunoglobulin
heavy chain locus, an event mediated by AID. Moreover, we show in our preliminary data that BAFF
synergizes with EBV to induce AID. Thus, the elevated population of latently infected B cells would be induced
to express AID increasing the risk for the c-myc translocation. Utilizing lymphocytes analyzed ex vivo, EBV+ B
cell lines, and in pediatric clinical samples from our field site in Kisumu, Kenya, we will test two key predictions
based on our model. First, that release of excessive heme by lysis of RBC during malaria results in EBV
reactivation in plasma cells and expansion of the latently infected B cell pool. Second, that increases in BAFF
during malaria results in aberrant AID expression in EBV-positive B cells. Dysregulation of EBV persistence
likely contributes not only to BL but also to other EBV-associated malignancies where co-factors are required
for emergence of disease. Lessons learned from studying the etiology of BL could potentially be used for
understanding the etiology of other EBV associated malignancies.